MaxCyte, Inc.

MXCTNASDAQHealthcare● Active

$1.15

+$0.01(+0.88%)

Market Cap$123189923

P/E Ratio—

52W High$2.4

52W Low$0.643

Avg Volume998K

Open$1.17

Beta1.67

Overview

MaxCyte, Inc. (MXCT) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

MXCT · free cash flow · updated Jun 8, 2026

Core FCF metrics

MXCT · FCF · TTM · margin & CAGR

Free cash flow was −$36.2M for FY2025 (fiscal year ending 2025-12-31), down 23.6% year-over-year The FCF margin was -109.5%.

FY2025 Free Cash Flow−$36.2M▼ -23.6% YoY

Trailing 12M (TTM)−$29.5Mtrailing 4 quarters sum

FCF Margin-109.5%−$36.2M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

MXCT · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$34.4M(2M)−$36.2M▼ 23.6%-109.5%

FY2024−$27.6M(2M)−$29.3M▼ 15.3%-75.8%

FY2023−$21.7M(4M)−$25.4M▲ +23.7%-61.5%

FY2022−$14.8M(18M)−$33.3M▼ 129.2%-75.2%

FY2021−$10.7M(4M)−$14.5M▼ 33.7%-42.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

MXCT · P/FCF · FCF yield · FCF per share

MaxCyte, Inc. (MXCT) reported negative free cash flow of −$0.04B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

MXCT · cash flow statement · operating / investing / financing

For FY2025, MaxCyte, Inc. generated −$34.4M in operating cash flow and spent 2M in capital expenditures, yielding −$36.2M in free cash flow.

Operating Activities

−$34.4M

Cash from core business operations

2025-12-31

Investing Activities

+$25.9M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$0.7M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$34.4M) − |CapEx| (2M) = FCF (−$36.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

MXCT vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

MaxCyte, Inc.YOU

MXCT

−$36.2M-23.6%-109.5%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

MaxCyte, Inc. (MXCT) reported free cash flow of −$36.2M for FY2025 (fiscal year ending 2025-12-31), down 23.6% year-over-year. The FCF margin was -109.5%.

MaxCyte, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 14 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

MXCT free cash flow · 8 questions

MaxCyte, Inc. free cash flow was −$36.2M for FY2025, down 23.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$29.5M.

MXCT free cash flowMXCT FCFMXCT FCF 2025MXCT free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · MaxCyte, Inc. · MaxCyte, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026